Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Gallagher FA"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 27
Tytuł:
Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.
Autorzy:
Welsh SJ; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK Cambridge Centre Urological Malignancies Programme, University of Cambridge, Cambridge, UK.
Thompson N; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Warren A; Cancer Research UK Cambridge Centre Urological Malignancies Programme, University of Cambridge, Cambridge, UK.; Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Priest AN; Department of Radiology, University of Cambridge, Cambridge, UK.
Barrett T; Cancer Research UK Cambridge Centre Urological Malignancies Programme, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK.
Ursprung S; Cancer Research UK Cambridge Centre Urological Malignancies Programme, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK.
Gallagher FA; Cancer Research UK Cambridge Centre Urological Malignancies Programme, University of Cambridge, Cambridge, UK.; Department of Radiology, University of Cambridge, Cambridge, UK.
Zaccagna F; Department of Radiology, University of Cambridge, Cambridge, UK.
Stewart GD; Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK Cambridge Centre Urological Malignancies Programme, University of Cambridge, Cambridge, UK.
Fife KM; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK Cambridge Centre Urological Malignancies Programme, University of Cambridge, Cambridge, UK.
Matakidou A; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK Cambridge Centre Urological Malignancies Programme, University of Cambridge, Cambridge, UK.; GlaxoSmithKline, Brentford, UK.
Machin AJ; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Qian W; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Ingleson V; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Mullin J; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Riddick ACP; Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK Cambridge Centre Urological Malignancies Programme, University of Cambridge, Cambridge, UK.
Armitage JN; Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK Cambridge Centre Urological Malignancies Programme, University of Cambridge, Cambridge, UK.
Connolly S; Department of Urology, Mater Misericordiae University Hospital, University College Dublin, Dublin 7, Ireland.
Eisen TGQ; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK Cambridge Centre Urological Malignancies Programme, University of Cambridge, Cambridge, UK.; Roche, Welwyn Garden City, UK.
Pokaż więcej
Źródło:
BJU international [BJU Int] 2022 Aug; Vol. 130 (2), pp. 244-253. Date of Electronic Publication: 2021 Nov 02.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Carcinoma, Renal Cell*/diagnostic imaging
Carcinoma, Renal Cell*/drug therapy
Carcinoma, Renal Cell*/surgery
Kidney Neoplasms*/diagnostic imaging
Kidney Neoplasms*/drug therapy
Kidney Neoplasms*/surgery
Biomarkers ; Humans ; Indoles/therapeutic use ; Necrosis/drug therapy ; Pyrroles/therapeutic use ; Sunitinib/therapeutic use ; Vascular Endothelial Growth Factor C/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Hyperpolarized C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma-A Proof of Principle Study.
Autorzy:
Ursprung S; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Woitek R; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
McLean MA; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Priest AN; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Crispin-Ortuzar M; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Brodie CR; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Gill AB; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Gehrung M; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Beer L; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Riddick ACP; Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Field-Rayner J; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Grist JT; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Deen SS; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Riemer F; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Kaggie JD; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Zaccagna F; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Duarte JAG; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Locke MJ; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Frary A; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Aho TF; Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Armitage JN; Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Casey R; Department of Endocrinology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Mendichovszky IA; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Welsh SJ; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.; Department of Surgery, University of Cambridge, Cambridge CB2 0QQ, UK.
Barrett T; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Graves MJ; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Eisen T; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Mitchell TJ; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.; Department of Surgery, University of Cambridge, Cambridge CB2 0QQ, UK.; Wellcome Sanger Institute, Hinxton CB10 1RQ, UK.
Warren AY; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Pathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Brindle KM; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Sala E; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Stewart GD; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.; Department of Surgery, University of Cambridge, Cambridge CB2 0QQ, UK.
Gallagher FA; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Jan 11; Vol. 14 (2). Date of Electronic Publication: 2022 Jan 11.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effects of Multi-Shell Free Water Correction on Glioma Characterization.
Autorzy:
Starck L; Department of Physics and Technology, University of Bergen, N-5007 Bergen, Norway.; Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, University of Bergen, N-5021 Bergen, Norway.
Zaccagna F; Department of Biomedical and Neuromotor Sciences, University of Bologna, 40125 Bologna, Italy.; IRCCS Istituto delle Scienze Neurologiche di Bologna, Functional and Molecular Neuroimaging Unit, Bellaria Hospital, 40139 Bologna, Italy.
Pasternak O; Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Gallagher FA; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Grüner R; Department of Physics and Technology, University of Bergen, N-5007 Bergen, Norway.; Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, University of Bergen, N-5021 Bergen, Norway.
Riemer F; Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, University of Bergen, N-5021 Bergen, Norway.
Pokaż więcej
Źródło:
Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2021 Dec 17; Vol. 11 (12). Date of Electronic Publication: 2021 Dec 17.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
Autorzy:
Ursprung S; CRUK Cambridge Centre, University of Cambridge, Cambridge, UK.
Mossop H; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Gallagher FA; CRUK Cambridge Centre, University of Cambridge, Cambridge, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Sala E; CRUK Cambridge Centre, University of Cambridge, Cambridge, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Skells R; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; AstraZeneca, Cambridge, UK.
Sipple JAN; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Mitchell TJ; CRUK Cambridge Centre, University of Cambridge, Cambridge, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Wellcome Sanger Institute, Hinxton, UK.
Chhabra A; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Fife K; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Matakidou A; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Young G; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Walker A; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Thomas MG; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Ortuzar MC; CRUK Cambridge Centre, University of Cambridge, Cambridge, UK.
Sullivan M; Oxford University Hospitals National Health Service Foundation Trust, Oxford, UK.
Protheroe A; Oxford University Hospitals National Health Service Foundation Trust, Oxford, UK.
Oades G; Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK.
Venugopal B; Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Warren AY; CRUK Cambridge Centre, University of Cambridge, Cambridge, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Stone J; AstraZeneca, Cambridge, UK.
Eisen T; CRUK Cambridge Centre, University of Cambridge, Cambridge, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Wason J; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK.
Welsh SJ; CRUK Cambridge Centre, University of Cambridge, Cambridge, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Stewart GD; CRUK Cambridge Centre, University of Cambridge, Cambridge, UK. .; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Nov 18; Vol. 21 (1), pp. 1238. Date of Electronic Publication: 2021 Nov 18.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Bayes Theorem*
Carcinoma, Renal Cell*/blood supply
Carcinoma, Renal Cell*/diagnostic imaging
Carcinoma, Renal Cell*/drug therapy
Carcinoma, Renal Cell*/pathology
Kidney Neoplasms*/blood supply
Kidney Neoplasms*/diagnostic imaging
Kidney Neoplasms*/drug therapy
Kidney Neoplasms*/pathology
Humans ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biopsy ; Capillary Permeability/drug effects ; Kidney/pathology ; Lymphocytes, Tumor-Infiltrating ; Magnetic Resonance Imaging ; Medical Futility ; Nephrectomy ; Non-Randomized Controlled Trials as Topic ; Phthalazines/therapeutic use ; Piperazines/therapeutic use ; Proof of Concept Study ; Quinazolines/therapeutic use ; Treatment Outcome ; Tumor Burden ; Clinical Trials, Phase II as Topic ; Multicenter Studies as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma.
Autorzy:
Ursprung S; University of Cambridge, Cambridge, United Kingdom.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.
Priest AN; University of Cambridge, Cambridge, United Kingdom.; Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom.
Zaccagna F; University of Cambridge, Cambridge, United Kingdom.
Qian W; University of Cambridge, Cambridge, United Kingdom.; Cambridge Cancer Trial Centre, Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Machin A; University of Cambridge, Cambridge, United Kingdom.; Cambridge Cancer Trial Centre, Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Stewart GD; University of Cambridge, Cambridge, United Kingdom.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom.
Warren AY; University of Cambridge, Cambridge, United Kingdom.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom.
Eisen T; University of Cambridge, Cambridge, United Kingdom.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom.
Welsh SJ; University of Cambridge, Cambridge, United Kingdom.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom.
Gallagher FA; University of Cambridge, Cambridge, United Kingdom.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.
Barrett T; University of Cambridge, Cambridge, United Kingdom.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Oct 26; Vol. 16 (10), pp. e0258988. Date of Electronic Publication: 2021 Oct 26 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiparametric Magnetic Resonance Imaging*
Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Sunitinib/*therapeutic use
Aged ; Carcinoma, Renal Cell/diagnostic imaging ; Carcinoma, Renal Cell/pathology ; Female ; Humans ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Neoadjuvant Therapy ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
In Vivo Cell Tracking Using PET: Opportunities and Challenges for Clinical Translation in Oncology.
Autorzy:
Lechermann LM; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.
Lau D; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.
Attili B; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.
Aloj L; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.; Department of Nuclear Medicine, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Gallagher FA; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Aug 11; Vol. 13 (16). Date of Electronic Publication: 2021 Aug 11.
Typ publikacji:
Journal Article; Review
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.
Autorzy:
Coen O; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Corrie P; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Marshall H; University of Leeds, Leeds, UK.; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
Plummer R; Newcastle University, Newcastle upon Tyne, UK.
Ottensmeier C; University of Southampton, Southampton, UK.
Hook J; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Bell S; University of Leeds, Leeds, UK.; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
Sagoo GS; University of Leeds, Leeds, UK.
Meads D; University of Leeds, Leeds, UK.
Bestall J; University of Leeds, Leeds, UK.
Velikova G; Leeds Teaching Hospitals NHS Trust, Leeds, UK.; University of Leeds, Leeds, UK.; Leeds Institute of Medical Research at St James's University Hospital, Leeds, UK.
Gallagher FA; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; University of Cambridge, Cambridge, UK.
Smith A; University of Leeds, Leeds, UK.; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
Howard H; University of Leeds, Leeds, UK.; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
Mason E; University of Leeds, Leeds, UK.; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
Katona E; University of Leeds, Leeds, UK.; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
Silva S; Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield, UK.; University of Sheffield, Sheffield, UK.
Collinson M; University of Leeds, Leeds, UK.; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
Rodwell S; University of Sheffield, Sheffield, UK.; Melanoma Focus, Cambridge, UK.
Danson S; Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield, UK. .; University of Sheffield, Sheffield, UK. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Jul 01; Vol. 21 (1), pp. 761. Date of Electronic Publication: 2021 Jul 01.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antibodies, Monoclonal/*therapeutic use
Immunotherapy/*methods
Melanoma/*drug therapy
Programmed Cell Death 1 Receptor/*therapeutic use
Antibodies, Monoclonal/pharmacology ; Humans ; Quality of Life
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Investigating the relationship between diffusion kurtosis tensor imaging (DKTI) and histology within the normal human brain.
Autorzy:
Maiter A; Department of Radiology, University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.
Riemer F; Department of Radiology, University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; MMIV, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
Allinson K; Department of Pathology, Addenbrooke's Hospital NHS Foundation Trust, Cambridge, UK.
Zaccagna F; Department of Radiology, University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.
Crispin-Ortuzar M; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Gehrung M; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
McLean MA; Department of Radiology, University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Priest AN; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Grist J; Department of Radiology, University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.
Matys T; Department of Radiology, University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.
Graves MJ; Department of Radiology, University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Gallagher FA; Department of Radiology, University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Apr 23; Vol. 11 (1), pp. 8857. Date of Electronic Publication: 2021 Apr 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Brain/*diagnostic imaging
Diffusion Tensor Imaging/*methods
Adult ; Female ; Humans ; Male ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Assessing robustness of carotid artery CT angiography radiomics in the identification of culprit lesions in cerebrovascular events.
Autorzy:
Le EPV; Department of Medicine, University of Cambridge, Cambridge, UK.
Rundo L; Department of Radiology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.
Tarkin JM; Department of Medicine, University of Cambridge, Cambridge, UK.
Evans NR; Department of Medicine, University of Cambridge, Cambridge, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Chowdhury MM; Division of Vascular Surgery, Department of Surgery, University of Cambridge, Cambridge, UK.
Coughlin PA; Division of Vascular Surgery, Department of Surgery, University of Cambridge, Cambridge, UK.
Pavey H; Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK.
Wall C; Department of Medicine, University of Cambridge, Cambridge, UK.
Zaccagna F; Department of Radiology, University of Cambridge, Cambridge, UK.; Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.
Gallagher FA; Department of Radiology, University of Cambridge, Cambridge, UK.
Huang Y; Department of Radiology, University of Cambridge, Cambridge, UK.; EPSRC Centre for Mathematical Imaging in Healthcare, University of Cambridge, Cambridge, UK.
Sriranjan R; Department of Medicine, University of Cambridge, Cambridge, UK.
Le A; School of Medicine, University of Leeds, Leeds, UK.
Weir-McCall JR; Department of Radiology, University of Cambridge, Cambridge, UK.
Roberts M; EPSRC Centre for Mathematical Imaging in Healthcare, University of Cambridge, Cambridge, UK.; Oncology R&D, AstraZeneca, Cambridge, UK.; Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, UK.
Gilbert FJ; Department of Radiology, University of Cambridge, Cambridge, UK.
Warburton EA; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Schönlieb CB; EPSRC Centre for Mathematical Imaging in Healthcare, University of Cambridge, Cambridge, UK.; Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, UK.
Sala E; Department of Radiology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK.
Rudd JHF; Department of Medicine, University of Cambridge, Cambridge, UK. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Feb 10; Vol. 11 (1), pp. 3499. Date of Electronic Publication: 2021 Feb 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Computed Tomography Angiography*/methods
Image Processing, Computer-Assisted*/methods
Machine Learning*
Carotid Arteries/*physiology
Aged ; Aged, 80 and over ; Algorithms ; Female ; Humans ; Male ; Middle Aged ; Tomography, X-Ray Computed/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The role of [  Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRA gastrointestinal stromal tumours (GIST).
Autorzy:
Aloj L; Department of Radiology, University of Cambridge, Cambridge, CB2 0QQ, UK.; Department of Nuclear Medicine, Cambridge University Hospitals Foundation Trust, Cambridge, CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, Cambridge, UK.
Giger O; Department of Pathology, University of Cambridge, Cambridge, CB2 0QQ, UK.
Mendichovszky IA; Department of Radiology, University of Cambridge, Cambridge, CB2 0QQ, UK.; Department of Nuclear Medicine, Cambridge University Hospitals Foundation Trust, Cambridge, CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, Cambridge, UK.
Challis BG; Department of Endocrinology, Cambridge University Hospitals Foundation Trust, Cambridge, CB2 0QQ, UK.
Ronel M; Department of Pathology, University of Cambridge, Cambridge, CB2 0QQ, UK.
Harper I; Department of Nuclear Medicine, Cambridge University Hospitals Foundation Trust, Cambridge, CB2 0QQ, UK.
Cheow H; Department of Nuclear Medicine, Cambridge University Hospitals Foundation Trust, Cambridge, CB2 0QQ, UK.
Hoopen RT; Department of Oncology, University of Cambridge, Cambridge, CB2 0QQ, UK.
Pitfield D; Department of Endocrinology, Cambridge University Hospitals Foundation Trust, Cambridge, CB2 0QQ, UK.
Gallagher FA; Department of Radiology, University of Cambridge, Cambridge, CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, Cambridge, UK.
Attili B; Department of Radiology, University of Cambridge, Cambridge, CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, Cambridge, UK.
McLean M; Cancer Research UK Cambridge Centre, Cambridge, UK.
Jones RL; Department of Medical Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, SW3 6JJ, UK.
Dileo P; Department of Medical Oncology, University College London Hospital Foundation Trust, London, NW1 2PG, UK.
Bulusu VR; Department of Medical Oncology, Cambridge University Hospitals Foundation Trust, Cambridge, CB2 0QQ, UK.
Maher ER; Department of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre and Cancer Research UK Cambridge Centre, Cambridge, CB2 OQQ, UK.
Casey RT; Department of Endocrinology, Cambridge University Hospitals Foundation Trust, Cambridge, CB2 0QQ, UK. .; Department of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre and Cancer Research UK Cambridge Centre, Cambridge, CB2 OQQ, UK. .
Pokaż więcej
Źródło:
EJNMMI research [EJNMMI Res] 2021 Jan 14; Vol. 11 (1), pp. 5. Date of Electronic Publication: 2021 Jan 14.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma.
Autorzy:
Gill AB; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0RE, UK.; Imaging Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Rundo L; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Wan JCM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Lau D; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Zawaideh JP; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Woitek R; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Zaccagna F; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Beer L; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Gale D; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0RE, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Sala E; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Couturier DL; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Corrie PG; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Rosenfeld N; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0RE, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Gallagher FA; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0RE, UK.; Imaging Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2020 Nov 24; Vol. 12 (12). Date of Electronic Publication: 2020 Nov 24.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Magnetic resonance fingerprinting of the pancreas at 1.5 T and 3.0 T.
Autorzy:
Serrao EM; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK, Cambridge, UK.
Kessler DA; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Carmo B; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Beer L; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Brindle KM; Cancer Research UK, Cambridge, UK.
Buonincontri G; IMAGO7 Foundation, Pisa, Italy.
Gallagher FA; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK, Cambridge, UK.
Gilbert FJ; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK, Cambridge, UK.
Godfrey E; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.
Graves MJ; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
McLean MA; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK, Cambridge, UK.
Sala E; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Cancer Research UK, Cambridge, UK.
Schulte RF; GE Healthcare, Munich, Germany.
Kaggie JD; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK. .; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Oct 16; Vol. 10 (1), pp. 17563. Date of Electronic Publication: 2020 Oct 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Magnetic Resonance Imaging*
Respiration*
Image Processing, Computer-Assisted/*methods
Pancreas/*diagnostic imaging
Adult ; Algorithms ; Female ; Humans ; Male ; Motion ; Pattern Recognition, Automated ; Phantoms, Imaging ; Prospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Detection limit of Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI.
Autorzy:
Lechermann LM; Department of Radiology, University of Cambridge, Cambridge, UK. .; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. .
Manavaki R; Department of Radiology, University of Cambridge, Cambridge, UK.
Attili B; Department of Radiology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Lau D; Department of Radiology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Jarvis LB; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Fryer TD; Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Bird N; Department of Nuclear Medicine, Addenbrooke's Hospital, Cambridge, UK.
Aloj L; Department of Radiology, University of Cambridge, Cambridge, UK.; Department of Nuclear Medicine, Addenbrooke's Hospital, Cambridge, UK.
Patel N; Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.
Basu B; Department of Oncology, University of Cambridge, Cambridge, UK.
Cleveland M; GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, UK.
Aigbirhio FI; Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Jones JL; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Gallagher FA; Department of Radiology, University of Cambridge, Cambridge, UK. .; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. .
Pokaż więcej
Źródło:
EJNMMI research [EJNMMI Res] 2020 Jul 14; Vol. 10 (1), pp. 82. Date of Electronic Publication: 2020 Jul 14.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
C Pyruvate Transport Across the Blood-Brain Barrier in Preclinical Hyperpolarised MRI.
Autorzy:
Miller JJ; Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford, UK. .; Department of Physics, Clarendon Laboratory, University of Oxford, Oxford, UK. .; Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital, Oxford, UK. .
Grist JT; Department of Radiology, University of Cambridge, Cambridge, UK.
Serres S; Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.; School of Life Sciences, University of Nottingham, Nottingham, UK.
Larkin JR; Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
Lau AZ; Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Canada.
Ray K; Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.; Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Fisher KR; Department of Chemistry, University of Oxford, Oxford, UK.
Hansen E; MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Tougaard RS; MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark.
Nielsen PM; MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Lindhardt J; MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Laustsen C; MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Gallagher FA; Department of Radiology, University of Cambridge, Cambridge, UK.
Tyler DJ; Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford, UK.; Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital, Oxford, UK.
Sibson N; Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2018 Oct 10; Vol. 8 (1), pp. 15082. Date of Electronic Publication: 2018 Oct 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Magnetic Resonance Imaging*
Blood-Brain Barrier/*metabolism
Carbon Isotopes/*metabolism
Pyruvic Acid/*metabolism
Animals ; Biological Transport ; Brain Neoplasms/secondary ; Cell Line, Tumor ; Female ; Humans ; Kinetics ; Mannitol/administration & dosage ; Mannitol/pharmacology ; Rats ; Swine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Ultra-early response assessment in lymphoma treatment: [ F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment.
Autorzy:
Mayerhoefer ME; Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. .
Raderer M; Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Jaeger U; Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Staber P; Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Kiesewetter B; Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Senn D; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Gallagher FA; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; Department of Radiology, Addenbrooke's Hospital, Cambridge, UK.
Brindle K; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Porpaczy E; Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Weber M; Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Berzaczy D; Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Simonitsch-Klupp I; Institute of Pathology, Medical University Vienna, Vienna, Austria.
Sillaber C; Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Skrabs C; Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Haug A; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2018 Jun; Vol. 45 (6), pp. 931-940. Date of Electronic Publication: 2018 Feb 26.
Typ publikacji:
Journal Article
MeSH Terms:
Magnetic Resonance Imaging*
Positron-Emission Tomography*
Hodgkin Disease/*diagnostic imaging
Lymphoma, Non-Hodgkin/*diagnostic imaging
Cell Count ; Female ; Fluorodeoxyglucose F18 ; Germany ; Glucose ; Humans ; Pregnancy ; Prospective Studies ; Radiopharmaceuticals ; Tomography, X-Ray Computed
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.
Autorzy:
Gnanapragasam VJ; Academic Urology Group, University of Cambridge, Box 279 (S4) Cambridge Biomedical Campus Cambridge CB2 0QQ, UK.; CamPARI Clinic, Box 41, Clinic 4A, Cambridge University Hospitals Trust, Cambridge CB2 0QQ UK.; Department of Urology, Cambridge University Hospitals Trust, Cambridge CB2 0QQ UK.
Burling K; Core Biochemical Assay Laboratory, Cambridge University Hospitals Trust, Cambridge CB2 0QQ UK.
George A; Academic Urology Group, University of Cambridge, Box 279 (S4) Cambridge Biomedical Campus Cambridge CB2 0QQ, UK.
Stearn S; Academic Urology Group, University of Cambridge, Box 279 (S4) Cambridge Biomedical Campus Cambridge CB2 0QQ, UK.
Warren A; Department of Pathology, Cambridge University Hospitals Trust,Cambridge CB2 0QQ UK.
Barrett T; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ UK.; Department of Radiology, Cambridge University Hospitals Trust, Cambridge CB2 0QQ UK.
Koo B; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ UK.
Gallagher FA; Department of Radiology, University of Cambridge, Cambridge CB2 0QQ UK.; Department of Radiology, Cambridge University Hospitals Trust, Cambridge CB2 0QQ UK.
Doble A; CamPARI Clinic, Box 41, Clinic 4A, Cambridge University Hospitals Trust, Cambridge CB2 0QQ UK.; Department of Urology, Cambridge University Hospitals Trust, Cambridge CB2 0QQ UK.
Kastner C; CamPARI Clinic, Box 41, Clinic 4A, Cambridge University Hospitals Trust, Cambridge CB2 0QQ UK.; Department of Urology, Cambridge University Hospitals Trust, Cambridge CB2 0QQ UK.
Parker RA; Edinburgh Clinical Trials Unit University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Edinburgh EH89AG UK.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2016 Oct 17; Vol. 6, pp. 35364. Date of Electronic Publication: 2016 Oct 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Magnetic Resonance Imaging*
Prostatic Neoplasms/*diagnosis
Prostatic Neoplasms/*physiopathology
Aged ; Aged, 80 and over ; Area Under Curve ; Biomarkers, Tumor/metabolism ; Biopsy ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Probability ; Prospective Studies ; Prostate/pathology ; Reproducibility of Results
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 27

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies